We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sloning Further Strengthens its Intellectual Property with new U.S. Patent
News

Sloning Further Strengthens its Intellectual Property with new U.S. Patent

Sloning Further Strengthens its Intellectual Property with new U.S. Patent
News

Sloning Further Strengthens its Intellectual Property with new U.S. Patent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sloning Further Strengthens its Intellectual Property with new U.S. Patent"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sloning, a supplier of synthetic biology tools was awarded US Patent No, 7,695,906. Sloning’s enabling platform technology - Slonomics® - allows researchers to increase the success rate of their screening for new and optimized therapeutic antibodies, proteins or industrial enzymes.

Slonomics®, a patented technology that uses a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries - 'one codon at a time'. For library production, multiple codons can be introduced in parallel at any desired sequence position.

The absence of functional bias and the ability to select and control delivery of up to 20 codons at any ratio results in exceptionally high quality libraries containing the complete set of desired mutants. In addition, mutated regions of varying length can also be incorporated in the design.

“The granted patent represents another key step in the ongoing development of our technology portfolio and allows the company to focus its efforts on developing additional innovative products and services for the protein and antibody engineer” says Dr. Jan Van den Brulle, Scientific Director of Sloning R&D.
Advertisement